LaunchTrends: Keytruda (Wave 1) is the first in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched malignant…
The poor prognosis of advanced malignant melanoma (melanoma) patients means that there is a significant need for effective therapies to treat patients in this indication and a large commercial…
LaunchTrends: Keytruda (Wave 1) is the first in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched malignant…
Oncology indications increasingly use predictive biomarkers to guide prescribing of costly therapies. However, uptake of targeted therapies in Brazil is highly dependent on incorporation into…
Oncology indications increasingly use predictive biomarkers to guide prescribing of costly therapies. However, uptake of targeted therapies in Mexico and Argentina is highly dependent on their…
Oncology is increasingly moving toward a personalized treatment approach, enlisting predictive biomarkers to guide therapy choice. This trend is already being felt in indications as varied as…
The era of personalized medicine is already well established in oncology. Biomarker-driven targeted therapies are among the top-selling oncology products today, and the impact of molecular…
Breakthrough therapy designation was introduced by the FDA in 2012 to expedite the drug development process for promising novel therapies for serious or life-threatening conditions. In 2013, of 28…
The launches of sipuleucel-T (Dendreon’s Provenge) and ipilimumab (Bristol-Myers Squibb’s Yervoy) in 2010 and 2011, respectively, represented the first notable immunotherapy approvals in…
Owing to the heterogeneity of cancer, oncology markets are increasingly focusing on personalized therapy approaches that are expected to provide greater efficacy gains. Driving this trend are…
LaunchTrends: Tafinlar and Mekinist is a series of three post-launch syndicated reports designed to track physician perception and uptake of newly launched Tafinlar (GlaxoSmithKline’s dabrafenib…